| Budget Amount *help |
¥16,250,000 (Direct Cost: ¥12,500,000、Indirect Cost: ¥3,750,000)
Fiscal Year 2016: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2015: ¥5,980,000 (Direct Cost: ¥4,600,000、Indirect Cost: ¥1,380,000)
Fiscal Year 2014: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
|
|---|
| Outline of Final Research Achievements |
We have demonstrated that the coexistence of the BRAF and the TERT promoter mutation is strongly associated with recurrence of thyroid cancers. This may be very useful for clinical management of thyroid cancer patients. However, the TERT promoter mutation is strongly correlated with higher age, implying that this marker is unfortunately not useful for young patients. The FOXE1 overexpression is observed in thyroid cancer tissues but may not have a strong influence on cancer development. We have also identified that the intracellular signaling cascade, PDGFbeta/JAK/STAT/NF-kappaB, plays an important role in the cancer stem properties in thyroid cancer stem cells. These results enable us to provide a molecular basis for a novel molecular-targeted therapy.
|
